LentiCRISPRv2-ACTB-C1 Citations (3)

Originally described in: Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene editing efficiency.
Yoshino Y, Endo S, Chen Z, Qi H, Watanabe G, Chiba N Sci Rep. 2019 Feb 7;9(1):1644. doi: 10.1038/s41598-018-38311-x. PubMed Journal

---

Articles Citing LentiCRISPRv2-ACTB-C1

Articles
Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway. Yanaihara N, Yoshino Y, Noguchi D, Tabata J, Takenaka M, Iida Y, Saito M, Yanagida S, Iwamoto M, Kiyokawa T, Chiba N, Okamoto A. Gynecol Oncol. 2023 Jan;168:83-91. doi: 10.1016/j.ygyno.2022.11.006. Epub 2022 Nov 17. PubMed
Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway. Iida Y, Yanaihara N, Yoshino Y, Saito M, Saito R, Tabata J, Kawabata A, Takenaka M, Chiba N, Okamoto A. Front Oncol. 2024 Feb 14;14:1302850. doi: 10.3389/fonc.2024.1302850. eCollection 2024. PubMed
Evaluating homologous recombination activity in tissues to predict the risk of hereditary breast and ovarian cancer and olaparib sensitivity. Motonari T, Yoshino Y, Haruta M, Endo S, Sasaki S, Miyashita M, Tada H, Watanabe G, Kaneko T, Ishida T, Chiba N. Sci Rep. 2024 Apr 8;14(1):7519. doi: 10.1038/s41598-024-57367-6. PubMed

If you have published an article using this material, please email us at to have your article added to this page.